Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.09)
# 3,425
Out of 4,814 analysts
60
Total ratings
25.86%
Success rate
-11.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $14.06 | +77.81% | 5 | Apr 9, 2025 | |
| INCY Incyte | Maintains: Hold | $74 → $72 | $58.22 | +23.67% | 9 | Mar 18, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $46.32 | +64.08% | 2 | Mar 11, 2025 | |
| BIIB Biogen | Maintains: Buy | $220 → $210 | $118.61 | +77.05% | 3 | Feb 13, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $839.90 | +23.59% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $173.00 | +25.43% | 3 | Feb 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,126 → $1,004 | $563.16 | +78.28% | 5 | Jan 8, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $22.15 | +44.50% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $13.41 | +273.00% | 6 | Nov 27, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $36 → $45 | $30.73 | +46.44% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $26.00 | +103.85% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.70 | +3,076.47% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.74 | +161.55% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $9.32 | +286.27% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $39.48 | +77.30% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $0.73 | +8,119.18% | 2 | Aug 11, 2023 |
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $14.06
Upside: +77.81%
Incyte
Mar 18, 2025
Maintains: Hold
Price Target: $74 → $72
Current: $58.22
Upside: +23.67%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $46.32
Upside: +64.08%
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $220 → $210
Current: $118.61
Upside: +77.05%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $839.90
Upside: +23.59%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $173.00
Upside: +25.43%
Regeneron Pharmaceuticals
Jan 8, 2025
Maintains: Buy
Price Target: $1,126 → $1,004
Current: $563.16
Upside: +78.28%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $22.15
Upside: +44.50%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $13.41
Upside: +273.00%
Scholar Rock Holding
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $30.73
Upside: +46.44%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $26.00
Upside: +103.85%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.70
Upside: +3,076.47%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.74
Upside: +161.55%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $9.32
Upside: +286.27%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $39.48
Upside: +77.30%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $0.73
Upside: +8,119.18%